Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.57 | — | — | 119.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 17.13 | 80.10 | 59.81 | 14.54 | 26.27 | 18.74 | 16.99 | 8.77 | 11.31 | 33.43 | 46.87 | 22.53 | 41.40 | 18.65 | 26.74 | 25.97 | 16.00 | 14.73 | 12.47 | 106.95 | 47.96 |
| — | +327.6% | +252.0% | +65.8% | +132.3% | -44.0% | -63.7% | -61.1% | -72.7% | +79.3% | +75.3% | -13.2% | +158.8% | +26.6% | +114.4% | -75.7% | -66.6% | -94.4% | -96.1% | -73.1% | -53.3% | |
| P/B Ratio | 5.31 | 5.73 | 7.83 | 8.87 | 18.60 | 4.40 | 1.31 | 1.31 | 2.64 | 2.82 | 3.81 | 3.03 | 3.10 | 3.38 | 3.70 | 2.77 | 2.47 | 3.29 | 3.07 | 4.52 | 3.53 |
| — | +30.2% | +495.7% | +578.7% | +604.9% | +56.2% | -65.5% | -57.0% | -14.8% | -16.6% | +3.1% | +9.7% | +25.1% | +2.6% | +20.6% | -38.8% | -30.0% | -12.4% | -4.2% | +62.8% | +126.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.99 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 49.78 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 49.78 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.2% | 100.0% | 89.1% | 99.0% | 99.9% | 98.6% | 97.6% | 94.6% | 99.0% | 96.9% | 81.1% | 79.4% | 86.4% | 96.1% | 95.0% | 94.7% | 92.2% | 95.3% | 96.6% | 78.8% | 55.3% |
| — | +1.4% | -8.7% | +4.6% | +0.9% | +1.8% | +20.4% | +19.2% | +14.5% | +0.8% | -14.6% | -16.2% | -6.2% | +0.8% | -1.7% | +20.2% | +66.8% | +33.0% | +56.4% | +151.4% | -21.2% | |
| Operating Margin | -149.6% | -834.7% | -440.2% | -99.1% | -102.9% | -715.4% | -433.1% | -178.2% | -101.6% | -416.7% | -461.3% | -304.7% | -538.1% | -155.8% | -278.4% | -346.7% | -175.2% | -93.0% | -122.1% | -2941.5% | -310.8% |
| — | -16.7% | -1.6% | +44.4% | -1.2% | -71.7% | +6.1% | +41.5% | +81.1% | -167.5% | -65.7% | +12.1% | -207.2% | -67.5% | -127.9% | +88.2% | +43.6% | +94.2% | +94.9% | +17.0% | +84.2% | |
| Net Margin | -436.5% | 138.6% | -279.0% | 12.9% | -809.0% | -1101.8% | -275.6% | -114.1% | -80.3% | -409.1% | -453.0% | -228.7% | -570.6% | -162.1% | -183.2% | -331.8% | -202.4% | -148.5% | -135.3% | -3019.8% | -355.3% |
| — | +112.6% | -1.2% | +111.3% | -907.7% | -169.3% | +39.2% | +50.1% | +85.9% | -152.3% | -147.2% | +31.1% | -181.9% | -9.2% | -35.4% | +89.0% | +43.0% | +86.3% | +72.0% | -346.7% | +84.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -105.6% | 2.6% | -10.0% | 2.7% | -87.7% | -48.8% | -5.4% | -4.6% | -4.6% | -8.4% | -9.8% | -7.4% | -10.3% | -7.5% | -6.2% | -8.5% | -7.6% | -8.1% | -8.0% | -27.5% | -6.4% |
| — | +105.4% | -87.2% | +157.5% | -1803.2% | -484.4% | +45.6% | +37.8% | +55.3% | -12.1% | -58.6% | +12.7% | -35.1% | +8.1% | +22.9% | +69.1% | -18.6% | -103.5% | -501.6% | -1356.0% | +22.1% | |
| ROA | -56.3% | 1.4% | -4.3% | 0.8% | -33.0% | -30.1% | -3.7% | -3.1% | -3.0% | -5.5% | -6.2% | -4.6% | -6.5% | -4.7% | -3.7% | -5.0% | -4.5% | -4.8% | -4.4% | -19.0% | -5.9% |
| — | +104.6% | -17.8% | +127.0% | -984.7% | -451.7% | +41.1% | +32.3% | +53.4% | -17.3% | -69.2% | +7.6% | -43.6% | +3.6% | +16.9% | +73.7% | +22.7% | -32.3% | -270.0% | -1084.7% | +18.4% | |
| ROIC | -84.4% | -30.5% | -47.2% | -98.7% | — | -76.1% | -14.8% | -10.4% | -7.2% | -12.4% | -16.6% | -14.1% | -12.7% | -7.7% | -8.2% | -8.3% | -11.5% | -28.3% | -20.1% | -42.6% | -8.1% |
| — | +59.9% | -218.1% | -847.2% | — | -512.5% | +10.6% | +25.9% | +43.4% | -61.4% | -102.7% | -69.7% | -10.4% | +72.8% | +59.3% | +80.5% | -41.5% | -242.0% | -147.9% | -512.2% | -21.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.04 | 0.05 | 0.06 | 0.13 | 0.05 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 |
| — | -15.9% | +57.2% | +71.0% | +197.0% | +3.6% | -37.0% | -31.4% | -8.1% | -7.6% | -13.0% | -12.1% | +28.0% | +85.4% | +75.7% | +75.7% | +58.9% | +9.8% | -1.5% | -23.3% | -27.9% | |
| Debt / EBITDA | — | 1.49 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.20 | 6.61 | 6.89 | 5.20 | 4.50 | 4.08 | 3.82 | 3.65 | 2.48 | 2.64 | 2.71 | 2.14 | 2.74 | 3.02 | 2.88 | 3.16 | 3.01 | 2.95 | 3.33 | 2.37 | 7.77 |
| — | +62.1% | +80.5% | +42.6% | +81.5% | +54.2% | +41.1% | +70.5% | -9.4% | -12.5% | -6.1% | -32.3% | -9.1% | +2.4% | -13.4% | +33.5% | -61.2% | -72.1% | -65.9% | -58.2% | +51.6% | |
| Quick Ratio | 5.20 | 6.61 | 6.89 | 5.20 | 4.50 | 4.08 | 3.82 | 3.65 | 2.48 | 2.64 | 2.71 | 2.14 | 2.74 | 3.02 | 2.88 | 3.16 | 3.01 | 2.95 | 3.33 | 2.37 | 7.77 |
| — | +62.1% | +80.5% | +42.6% | +81.5% | +54.2% | +41.1% | +70.5% | -9.4% | -12.5% | -6.1% | -32.3% | -9.1% | +2.4% | -13.4% | +33.5% | -61.2% | -72.1% | -65.9% | -58.2% | +51.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LCTX stock.
Lineage Cell Therapeutics, Inc.'s current P/E is -3.6x. The average P/E over the last 1 quarters is 119.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Lineage Cell Therapeutics, Inc.'s current operating margin is -149.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Lineage Cell Therapeutics, Inc.'s business trajectory between earnings reports.